Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Krishnansu S. Tewari, Pamela Salman, Edwin Hoyos Usta, Eduardo Yañez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Arkhipov Alexander, Sarper Toker, Kan Li, Stephen J. O’Keefe, Bradley J. Monk
Abstract
(Abstracted from N Engl J Med 2021;385:1856–1867) Platinum-based chemotherapy plus bevacizumab and paclitaxel is the standard first-line therapy for persistent, recurrent, or metastatic cervical cancer. The phase 2 KEYNOTE-158 trial found evidence of a response to pembrolizumab among patients with programmed death ligand-1 (PD-L1) positive cervical cancer.
Topics & Concepts
MedicinePembrolizumabBevacizumabOncologyChemotherapyCervical cancerInternal medicinePaclitaxelCancerImmunotherapyCancer Immunotherapy and BiomarkersEndometrial and Cervical Cancer Treatments